Breast Cancer Clinical Trial
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
Summary
This study is being done to help the investigators determine how accurate the sentinel lymph node biopsy (SLNB) procedure is in identifying residual cancer cells after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer.
Eligibility Criteria
Inclusion Criteria:
Female patients over 18 years of age with biopsy-proven breast cancer
Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
Exclusion Criteria:
Patients with a prior history of ipsilateral breast cancer
Pregnant patients
Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
Patients not consenting to ALND
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Basking Ridge New Jersey, 07920, United States More Info
Montvale New Jersey, 07645, United States More Info
New York New York, 10065, United States More Info
Principal Investigator
Uniondale New York, 11553, United States More Info
How clear is this clinincal trial information?